Government policies and regulations have created an environment hostile to research and innovation.
Advanced clinical trials in Canada, which were consistent between 2015 and 2019, decreased by 26 per cent in 2020.
Drug manufacturers may forgo sales in Canada to increase average reference prices.
Forcing manufacturers of high-cost drugs to reduce their prices by up to 80 per cent is unsustainable.
Profit incentivizes innovation and helps fund research and development.
Pharmaceutical manufacturers take on a significant investment risk to develop new drugs.